QIAGEN N.V. (QGEN) vs RadNet, Inc. (RDNT)

QIAGEN N.V. and RadNet, Inc. are both Diagnostics & Research companies. QIAGEN N.V. is the larger, with a market value of $9.3B against $5.6B — 1.7× the size. RadNet, Inc. has negative trailing earnings, so its P/E is not meaningful; QIAGEN N.V. trades at 22.6×. RadNet, Inc. grew revenue faster over the last twelve months: 18.9% against 2.96%. QIAGEN N.V. has the higher net margin (19.5% vs −0.93%) and the higher return on invested capital (6.62% vs 2.24%). Across the 21 metrics below, QIAGEN N.V. leads on 17 and RadNet, Inc. on 4.

Valuation

Metric QGEN RDNT Diagnostics & Research median
P/E 22.64 n/m 33.95
P/S 4.34 2.43 4.87
P/B 2.72 3.95 3.12
Price to free cash flow 20.69 170.43 34.02
EV/EBITDA 15.31 19.86 25.20
EV/Sales 4.75 2.69 5.66
Earnings yield 4.42% (0.38%) (1.75%)
Free cash flow yield 4.83% 0.59% (0.13%)

Profitability

Metric QGEN RDNT Diagnostics & Research median
Gross margin 62.20% 11.53% 50.89%
Operating margin 21.21% 3.12% (8.57%)
Net margin 19.49% (0.93%) (6.37%)
Free cash flow margin 20.98% 3.28% 0.00%
Return on equity 11.93% (1.64%) (2.92%)
Return on assets 6.99% (0.55%) (6.71%)
Return on invested capital 6.62% 2.24% 0.00%

Growth

Metric QGEN RDNT Diagnostics & Research median
Revenue growth (TTM) 2.96% 18.92% 7.69%
EPS growth (last fiscal year) 398.07% (725.00%) —
Revenue growth, 5-year CAGR 2.25% 13.74% 7.40%
Net income growth, 5-year CAGR 3.42% 0.00% 0.00%

Health

Metric QGEN RDNT Diagnostics & Research median
Debt to equity 0.49 0.94 0.11
Current ratio 2.85 1.48 2.02
Net debt to EBITDA 0.84 1.16 0.78

Dividend

Metric QGEN RDNT Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio 0.00 0.00 0.00

Size

Metric QGEN RDNT Diagnostics & Research median
Market cap 9.26b 5.60b 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack